prodcode,dmdcode,gemscriptcode,therapyevents,productname,ingredient,strength,formulation,routeofadministration,bnftext,v12,v13,v14,v15,v16,v17,v18,v19,v20,v21,slashcountinchapter,bnfchapter
68805,2.87903110000e+16,46573021,10,Nintedanib 150mg capsules,Nintedanib esilate,150mg,Capsule,Oral,Antifibrotics/Protein Kinase Inhibitors,February 2017,46573021,,,,,,,,,1,3130000
63440,3.60639110000e+16,60817020,1,Epoprostenol 500microgram powder and solvent (pH10.5) for solution for infusion vials,Epoprostenol sodium,500microgram,Powder and solvent for solution for infusion,Intravenous,Antifibrotics,June 2015,3209001,,,,,,,,,0,3130000
64388,2.87902110000e+16,46571021,13,Nintedanib 100mg capsules,Nintedanib esilate,100mg,Capsule,Oral,Antifibrotics/Protein Kinase Inhibitors,October 2015,46571021,,,,,,,,,1,3130000
60325,2.23332110000e+16,15590021,4,Esbriet 267mg capsules (Roche Products Ltd),Pirfenidone,267mg,Capsule,Oral,Antifibrotics,July 2014,15590021,,,,,,,,,0,3130000
57782,2.23430110000e+16,15589021,66,Pirfenidone 267mg capsules,Pirfenidone,267mg,Capsule,Oral,Antifibrotics,October 2013,15589021,,,,,,,,,0,3130000
71494,3.46256110000e+16,77581021,11,Pirfenidone 801mg tablets,Pirfenidone,801mg,Tablet,Oral,Antifibrotics,January 2018,77581021,,,,,,,,,0,3130000
64998,3.60638110000e+16,60818020,4,Epoprostenol 1.5mg powder and solvent (pH10.5) for solution for infusion vials,Epoprostenol sodium,1.5mg,Powder and solvent for solution for infusion,Intravenous,Antifibrotics,December 2015,3209002,,,,,,,,,0,3130000
77751,3.46255110000e+16,77579021,0,Pirfenidone 267mg tablets,Pirfenidone,267mg,Tablet,Oral,Antifibrotics,August 2019,77579021,,,,,,,,,0,3130000
77569,3.07688110000e+16,60084021,1,Ofev 150mg capsules (Boehringer Ingelheim Ltd),Nintedanib esilate,150mg,Capsule,Oral,Antifibrotics/Cytotoxic Drugs,August 2019,60084021,,,,,,,,,1,3130000
